Tag: press release

Cuomo Seeks to Boost Organ and Tissue Donations in NYS with Lauren's Law

by BNMCin Homepage, Member Institution(s), NewsLeave a Comment on Cuomo Seeks to Boost Organ and Tissue Donations in NYS with Lauren's Law

With the help of Unyts, one the leading  procurement organizations in the nation, Western New York has one of the highest organ and tissue consent rates in the country. New York State, though, is the 3rd state with the lowest consent rates for organ and tissue donations in the U.S. With 113,000 people on the national waiting list for organ and tissue donations, 9,700 of them are residents of New York State, yet, the Empire State only has 18% of its adults registered as donors. The national average is 43%.
Beginning in October 2013, the number of New York State residents who become organ and tissue donors is expected to increase based on new language on the New York State Department of Motor Vehicles driver’s license wp-contentlication. A new bill signed into legislation by Governor Andrew Cuomo, called “Lauren’s Law,” requires wp-contentlicants to check one of the two options for organ donor registration. Applicants can either check “yes” or “skip this question” under the organ registration section.

Back in June, Lauren’s Law was passed by unanimous vote by the New York State Assembly and Senate. Governor Cuomo stated that “By adding this new language to DMV wp-contentlication forms, it is our hope that many more New Yorkers sign up to be on the list of those willing to donate an organ or tissue.” Cuomo recognized Senator David Carlucci (D-Rockland/Orange) and Assemblyman Felix Ortiz (D-Brooklyn) for their efforts to support the passing of the bill into law along with advocate Lauren Shields.

The President and CEO of Unyts, Mark Simon said that “[The bill] will result in increased donations and more opportunities for life safe and life enhancing transplants.”

Lauren Shields, who is now a 12 year old girl, received a heart transplant back in 2009. Officials named the law Lauren’s Law as a result of Shields’ advocacy efforts to help save lives by organ and tissue donations. Shields is a resident of Stony Point in Rockland County. She began her battle with heart failure when she was 9 years old, diagnosed with viral myocarditis (inflammation of the heart muscle), an illness preventing her heart from being able to pump blood through her body because it was so swollen. Today, as a recipient of a successful transplant and a healthy child, Shields aspires to become a cardiologist to help save lives.

For more about Shields’ story, watch the video below:

“I never want anyone to have to wait for a transplant like I did.” -Lauren Shields

To learn how to register and become a donor and help save a life, please visit www.unyts.org/get-involved/donor-registry/.

 

UB Ranked One of the World’s Best Universities by Times Higher Education

by BNMCin Homepage, Member Institution(s), NewsLeave a Comment on UB Ranked One of the World’s Best Universities by Times Higher Education

UB Ranked One of the World’s Best Universities by Times Higher Education

Times Higher Education has named the University at Buffalo as one of the world’s top 200 universities.

UB is ranked 198th in the 2012-13 Times Higher Education World University Rankings, up from last year’s ranking among the top 201 to 225 universities worldwide. The assessment uses 13 performance indicators to analyze how well a university is doing in core missions including teaching, research, knowledge transfer and international outlook.

“This is very good news. Moving into the top-200 will enhance UB’s already-strong reputation overseas and help us attract outstanding students from around the world,” said Stephen C. Dunnett, PhD, UB professor and vice provost for international education.

“International students are particularly conscious of university rankings, and UB’s steady ascent in various international rankings in recent years — a reflection of our strong institutional commitment to excellence — is certainly well recognized and wp-contentreciated by students and their families overseas.”

Times Higher Education is a leading higher education magazine, and the recognition of UB as a top-200 university demonstrates UB’s growing global reputation. The data for the rankings were collected by Thomson Reuters, which considered about 700 institutions in 69 countries.

In recent years, UB has invested in recruiting additional high-quality faculty, attracting researchers from around the world to Western New York. These faculty members conduct research on some of the world’s most pressing problems, and provide students with an excellent education in the classroom.

Under President Satish K. Tripathi, UB has embarked on the next phase of its UB 2020 plan for academic excellence.  With the support of the NYSUNY 2020 legislation, signed into law last year by Gov. Andrew M. Cuomo, UB is in the midst of a historic transformation.  The university is hiring 250 new faculty over the next five years, offering new programs to enrich students’ academic experiences and opening new facilities on its three campuses, with the goal of becoming one the world’s leading public research universities and increasing its regional economic impact.

Abroad, the university has cultivated relationships with distinguished educational institutions throughout the world, cooperating with international partners on student exchanges, joint research projects and the delivery of degree programs overseas.

At home, UB consistently places in the top 20 in the United States for international student enrollment, according to annual data published by the Institute of International Education. In 2010-11, for instance, UB had 5,185 foreign students, the 17th largest population in the nation.

John DellaContrada; dellacon@buffalo.edu; 716-645-4601

UB Department of Medicine Names New Chief of Nephrology Division

by BNMCin Member Institution(s), NewsLeave a Comment on UB Department of Medicine Names New Chief of Nephrology Division

Release Date: October 1, 2012Contact: Ellen Goldbaum, goldbaum@buffalo.edu
University at Buffalo
716-645-4605

UB Department of Medicine Names New Chief of Nephrology Division

BUFFALO, N.Y. — Richard J. Quigg Jr., MD, professor of medicine at the University of Chicago and former chief of its nephrology section, has been named the inaugural Arthur M. Morris Chair in Nephrology and chief of the division of Nephrology in the Department of Medicine in the University at Buffalo School of Medicine and Biomedical Sciences.

A photo of Quigg is at http://www.buffalo.edu/news/13714.

The announcement was made by Anne B. Curtis, MD, Charles and Mary Bauer Professor and chair of the Department of Medicine in UB’s School of Medicine and Biomedical Sciences.

The primary focus of Quigg’s research laboratory is to identify pathogenic mechanisms that underlie kidney disease. He is nationally and internationally renowned for his research into diseases of the glomeruli. Glomerular diseases damage the clusters of blood vessels called glomeruli, which filter blood in the kidneys, letting protein and sometimes red blood cells leaks into the urine, ultimately interfering with proper kidney function.

Quigg’s research interests include the role of the complement system, a major factor in the body’s immune response and other defenses, in glomerular disease, lupus nephritis, and diabetic nephropathy. He uses a variety of contemporary techniques to investigate disease pathogenesis and to identify sites of potential therapeutic manipulation. In addition to using animal models, his lab is involved in clinical studies examining the role of the complement system in various kidney diseases and examining gene profiles from renal tissue obtained from patients with these conditions.

Quigg received his undergraduate and medical degrees from Boston University. He completed his medical residency at SUNY Stony Brook and research and clinical fellowships in nephrology at the Boston University Medical Center. He was wp-contentointed to the University of Chicago in 1994 as an associate professor, and was promoted to professor in 2001. He served as chief of the Section of Nephrology at the university and was director of its Functional Genomics Facility. Before joining the University of Chicago, he was an assistant professor at the Medical College of Virginia.

Investigational Brain Cancer Vaccine to Be Tested in Phase I Roswell Park Study

by BNMCin Member Institution(s), News, ResearchLeave a Comment on Investigational Brain Cancer Vaccine to Be Tested in Phase I Roswell Park Study

FOR IMMEDIATE RELEASESeptember 27, 2012
Contact: Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

Investigational Brain Cancer Vaccine to Be Tested in Phase I Roswell Park Study
Peptide vaccine targets cancer survival protein, putting tumor cells in a Catch 22

BUFFALO — A new clinical research study at Roswell Park Cancer Institute (RPCI) will test a first-of-its-kind cancer “vaccine” that may prove effective against many forms of solid-tumor cancers. The vaccine, to be investigated in a trial involving patients with brain cancer, generates an immune response that wp-contentears to put the target molecule, the cancer survival protein survivin, into a bind it can’t escape.

The peptide vaccine, developed at Roswell Park by Robert Fenstermaker, MD, and Michael Ciesielski, PhD, is based upon a specially engineered small protein molecule called a “peptide mimic.” Dr. Fenstermaker is principal investigator of the phase I clinical research study, which will test the safety and immunological effects of the vaccine in patients with two types of brain cancer: glioblastoma multiforme (GBM) and anaplastic glioma. Called SurVaxM, the injectable vaccine will initially be given in four doses to nine patients.

Survivin, produced by at least 80% of cancers, is a protein that helps cancer cells to survive under stressful conditions. It is present only in diseased cells, which are caught in an unwinnable situation when exposed to the vaccine.

“SurVaxM puts cancer cells in a Catch 22,” says Dr. Fenstermaker, who is Chair of RPCI’s Department of Neurosurgery and Director of the Institute’s Neuro-Oncology Program. “The vaccine kills tumor cells that express survivin. If the cells turn survivin off to escape the vaccine, they’re essentially committing suicide.”

The engineered peptide used in the vaccine is able to stimulate an immune response because the cancer recognizes it as a foreign molecule.

“We arrived at this peptide through reverse immunology,” notes Dr. Ciesielski. “We knew we wanted to target survivin because it is expressed by so many tumors. We looked at many survivin peptides trying to find the best one to use as our vaccine. Once we identified one that looked promising, we engineered it to be more potent and produce a better response by enlisting multiple arms of the immune system.”

In preclinical studies, the vaccine was effective against several cancers, including gliomas and prostate, ovarian, breast and kidney tumors that produce survivin. Studies in which human glioma, lymphoma and leukemia cells were exposed to the vaccine outside the body also produced a strong response. “In those earlier studies, the response was persistent,” Dr. Ciesielski says. “It wp-contentears that the vaccine continues to provide lasting immunity after the tumor has been eliminated.”

Roughly 15,000 people are newly diagnosed with glioblastomas and anaplastic gliomas in the U.S. every year. These cancers are very difficult to treat, and are often fatal.

“Survival rates for malignant gliomas have improved modestly over the last two decades, but better therapies are desperately needed,” Dr. Fenstermaker says. “We’re anxious to move ahead with this study and, hopefully, go on to larger studies in the years ahead, but we first have to show that this is a safe and well-tolerated drug for a group of terrible diseases.”

Because they enlist the body’s own cells to fight cancer, immune-based therapies generally have few adverse side effects. The trial is the fourth clinical research study launched through RPCI’s Center for Immunotherapy this year.

The study is National Cancer Institute trial no. NCT01250470. For more information about SurVaxM and this new phase I research study, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

Ciesielski and Fenstermaker credit early seed funding from donations with helping to move their research forward and generating additional dollars in new grant funding from organizations such as the National Institutes of Health/National Cancer Institute (R21 NS049309-01) and the American Cancer Society. Additional support from The Jayne and Phil Hubbell Family was instrumental in advancing the team’s research.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

-30-

Editor’s note: Photo caption: Robert Fenstermaker, MD, left, and Michael Ciesielski, PhD. Video interview with Drs. Fenstermaker and Ciesielski available at https://vimeo.com/48443468. For additional photos and multimedia, including B-roll video, send request to: annie.deck-miller@roswellpark.org.

Landmark Gift From Oishei Foundation for Children's Hospital

by BNMCin Member Institution(s), NewsLeave a Comment on Landmark Gift From Oishei Foundation for Children's Hospital

A $10 million donation to Kaleida Health means the brand new hospital will be named the John R. Oishei Children’s Hospital, continuing to serve the women and children of Buffalo. The donor, The John R. Oishei Foundation, named the facility after the late industrialist and philanthropist, John R. Oishei, who established the Foundation in 1940.
Jim Wadsworth, Chairman of the Foundation stated that “The primary reason [Oishei] began his philanthropy back in the 1940s was to benefit the children of his employees and of the community.” The mission of the Foundation is “to be a catalyst for change to enhance economic vitality and the quality of life for the Buffalo Niagara region.”

The unprecedented gift will enable the hospital to continue expanding the specialized health care services offered to its infant and women patients. The 430,000 sq. ft., 12-story facility will house a state-of-the-art Neonatal Intensive Care Unit which received a $2 million gift in August, a connected ambulatory care center, and a family resource center. In the future, plans include a Women’s Pavilion to house labor and delivery, post partum care, the regional perinatal center for high-risk pregnancies, and a women’s health center providing prenatal and gynecological care.

“Similar to how John R. Oishei sought the best technology available in his time to create the first automobile wiper blades and ultimately the Trico Products Corporation, the Foundation that now bears his name and legacy will share its resources to make advanced technologies and care available today to improve the health and lives of families throughout our community,” said James R. Kaskie, President and Chief Executive Officer of Kaleida Health.

Set to open in 2016, the John R. Oishei Children’s Hospital will sit on the corner of High and Ellicott Streets, across from the Buffalo General Medical Center.

Read more coverage about the gift below:

Oishei Gift Boosts Medical Campus

Oishei Makes $10M Pledge to New Children’s Hospital

Oishei Foundation Gives Hospital $10M

New Oishei Children’s Hospital Receives $10 Million Gift

Oishei Gifts $10 Million Towards New Children’s Hospital

 

 

 

 

 

J. Craig Venter Receives Honorary Doctorate, Extols Virtues of the CTRC, UB's Newest Research Facility

by BNMCin Homepage, Member Institution(s), News, ResearchLeave a Comment on J. Craig Venter Receives Honorary Doctorate, Extols Virtues of the CTRC, UB's Newest Research Facility
[ photograph ]“I’m actually jealous,” said J. Craig Venter, speaking of UB’s Clinical and Translational Research Center, after receiving the SUNY Honorary Doctorate in Science.

World-renowned genomic researcher calls UB facility “some of the most beautiful lab space I’ve seen.”

J. Craig Venter, PhD, the pioneering biologist who led the first team to sequence the human genome, received a State University of New York Honorary Doctorate in Science at the University at Buffalo on Sept. 20. The honorary degree was conferred on him at a ceremony that followed the grand opening of UB’s Clinical and Translational Research Center in the joint UB-Kaleida Health building in downtown Buffalo.

UB President Satish K. Triapthi called Venter “one of the 21st century’s most influential scientists and widely regarded as the world’s foremost leader in the field of genetic research.” He said he couldn’t think of a more fitting individual to honor on the occasion of the CTRC opening.

The degree was conferred on Venter by Angelo Fatta, UB Foundation board of directors chair, and SUNY Trustee Eunice Lewin.

Venter, a former UB and Roswell Park Cancer Institute scientist, developed a revolutionary strategy for rapid gene discovery while working at the National Institutes of Health. He later founded The Institute for Genomic Research and, in 1995, he and his team decoded the genome of the first free-living organism. At Celera Genomics, which he founded in 1998, Venter sequenced the human genome using new tools and techniques he and his team developed. The successful completion of this research culminated with the February 2001 publication of the human genome in the journal Science.

Speaking before the audience that gathered in the fifth floor atrium of the CTRC, Venter expressed his honest admiration for UB’s newest research facility.

“I’m actually jealous,” he said, after accepting the SUNY honorary degree. “This is some of the most beautiful lab space I’ve seen and the views are always improving.” Venter then described his newest building, now under construction on the University of California San Diego campus, which, he conceded, will have even better views because it is located right next to the Pacific Ocean.

In addition to the CTRC’s physical assets, Venter praised UB and Buffalo for committing to the creation of a life sciences economy. “I’m a strong believer that the future does rest in a bioeconomy,” he said.

Venter also gave an update on genomics, describing the massive amounts of digital information that the research has produced and the challenge caused by this “digitizing of biology.” While the mammalian genome has largely been completed, he said, there is plenty of genetic diversity on the planet that has yet to be discovered.

“By sequencing the microbiome, we find we are not alone,” he said. “In addition to the 2 million human genes we have, each of us also contains about 10 million additional microbe genes. We live in a microbial world; we are visitors here.”

He and his colleagues are also looking at the vast genetic diversity in the ocean. “Every time we take a sample of seawater, we see between 1 and 3 million genes that haven’t been seen before,” he said.

While noting that the idea that it’s possible to sequence your own genome for about $1,000 may be an overstatement, he said that personalized medicine based on a patient’s genetic information “will be a standard part of medicine within a few years.”

Venter is founder and president of the J. Craig Venter Institute, a not-for-profit, research and support organization dedicated to human, microbial, plant and environmental genomic research, the exploration of social and ethical issues in genomics, and alternative energy solutions through genomics. He and his team continue to blaze new trails in genomics research and have published numerous important papers covering such areas as the first complete diploid human genome, environmental genomics and synthetic genomics.

Venter also is founder and chief executive officer of the company Synthetic Genomics Inc., a privately held company commercializing genomic advances.

 

Ellen Goldbaum; goldbaum@buffalo.edu; 716-645-4605; @egoldbaum

UB Partners with Zimbabwe Universities to Create International Nanotechnology Center

by BNMCin Life Sciences Companies, Member Institution(s), News, ResearchLeave a Comment on UB Partners with Zimbabwe Universities to Create International Nanotechnology Center

For release: September 24, 2012Contact: Sara R. Saldi, saldi@buffalo.edu
University at Buffalo
716-645-4593

UB Partners with Zimbabwe Universities to Create International Nanotechnology Center

BUFFALO, N.Y. — With 14 percent of Zimbabwe’s population living with HIV/AIDS and tuberculosis as a co-infection, the need for new drugs and new formulations of available treatments is crucial.

To address these issues, two of the University at Buffalo’s leading research centers, the Institute for Lasers, Photonics and Biophotonics (ILPB), and the New York State Center of Excellence in Bioinformatics and Life Sciences have signed on to launch the Zimbabwe International Nanotechnology Center (ZINC) — a national nanotechnology research program — with the University of Zimbabwe (UZ) and the Chinhoyi University of Technology (CUT).

This collaborative program will initially focus on research in nanomedicine and biosensors at UZ and energy at CUT.  ZINC has grown out of the NIH Fogarty International Center, AIDS International Training and Research Program (AITRP) that was awarded to UB and UZ in 2008 to conduct HIV research training and build research capacity in Zimbabwe and neighboring countries in southern Africa.

UB faculty and research directors in the ZINC partnership include Paras N. Prasad, PhD, SUNY Distinguished Professor of Chemistry, Physics, Medicine and Electrical Engineering, the Samuel P. Capen Chair, executive director of ILPB; Gene D. Morse, PharmD, Professor of Pharmacy Practice, associate director of the New York State Center of Excellence in Bioinformatics and Life Sciences and director of the Translational Pharmacy Research Core; Alexander N. Cartwright, PhD, UB vice president for research and economic development and interim executive director of the New York State Center of Excellence in Bioinformatics and Life Sciences , who will work with Professor Levi Nyagura, UZ vice chancellor; Professor David T. Simbi, CUT vice chancellor, and Dr. Charles Maponga, PharmD, UZ pharmacy school director.

ZINC will establish a long-term international research and training platform in the field of nanotechnology, focused in areas that promote Zimbabwe’s strength, and advance the development of nanotechnology as an avenue for Zimbabwe’s commercial growth.

The UB ILPB and TPRC collaboration recognized that the fields of pharmacology and therapeutics have increasingly developed links with emerging areas within the field of nanosciences in an attempt to develop tissue/organ targeted strategies that will lead to disease treatment and eradication. Research teams will focus on emerging technologies, initially focused in nanobiotechnology and nanomedicine for health care.

“Developing nanoformulations for HIV and tuberculosis diagnostics and therapeutics, as well as new tuberculosis drug development, are just a few of the innovative strategies to address these co-infections that this research collaboration can provide,” said Morse.

“In addition, the development of new nanotechnology-related products will jumpstart the economy and foster new economic initiatives in Zimbabwe that will yield additional private-public partnerships.”

A photo of Morse is available at: http://www.buffalo.edu/news/13694.

Morse says that the current plans for a “Center of Excellence” in clinical and translational pharmacology in Harare at UZ will create a central hub in Africa, not just for Zimbabwe but for other countries to gain new training and capacity building in many exciting aspects of nanotechnology as well.

Morse adds that this initiative creates an opportunity for additional involvement from a number of UB centers such as those represented by UB’s Strategic Strengths in areas such as Health and Wellness across the Lifespan, Integrated Nanostructured Systems, Molecular Recognition in Biological Systems and Bioinformatics and Information and Computing Technology.

“With an international program like ZINC, we are hoping to attract pharmaceutical companies and biotechnology firms who will have similar interests in joining this unique partnership that will enhance the likelihood of economic success through efficient, innovative research.”

“Locally, these efforts will be linked to the growing Buffalo Niagara Medical Campus resulting in a truly global partnership with one anchor in Buffalo–a comprehensive ‘UB matrix’ of innovation and excellence,” says Morse.

All in One Day: Three Awards for the Buffalo Niagara Medical Campus

by BNMCin Campus-wide, Innovation Center, Member Institution(s), NewsLeave a Comment on All in One Day: Three Awards for the Buffalo Niagara Medical Campus

The Buffalo Niagara Medical Campus (BNMC) received three honors on the same day this week: the BNMC was named 2012 Outstanding Research/Science Park by the Association of University Research Parks (AURP); its Four Neighborhoods, One Community: Buffalo Niagara Medical Campus Master Plan Update has been awarded the 2012 Planning Excellence Award for Comprehensive Planning by the New York Upstate Chapter of the American Planning Association (NYUAPA); and the Thomas R. Beecher Innovation Center, owned and operated by the BNMC, Inc., received the Innovative Design Award by international trade organization Global Workspace Association.

2012 Outstanding Research/Science Park Award by Association of University Research Parks (AURP)

Patrick J. Whalen, Chief Operating Officer of the Buffalo Niagara Medical Campus, Inc., was on hand to accept the award at AURP’s annual conference in Madison, WI.

“The Association of University Research Parks is pleased to announce the 2012 Awards of Excellence recipients and has named the Buffalo Niagara Medical Campus the 2012 Outstanding Research Park,” said AURP President Kevin Byrne. “BNMC is a world-class medical campus that has created a strong community of innovation in Buffalo and throughout the region. We congratulate them for their outstanding achievements.”

AURP is a professional association of university related research and science parks. The association’s mission is to foster innovation, commercialization and economic growth through university, industry and government partnerships. More online at www.aurp.net.

Previous parks honored as Outstanding Research/Science Park of the Year include the Research Park at the University of Illinois at Urbana-Champaign; Virginia Tech Corporate Research Center; Innovation Place (Saskatoon, Saskatchewan, Canada); Sandia Science & Technology Park (Albuquerque, NM); and Centennial Campus at North Carolina State University.

Read more about the award here.

2012 Planning Excellence Award for Comprehensive Planning from the New York Upstate Chapter of the American Planning Association

In addition, NYUAPA announced that the Four Neighborhoods, One Community: Buffalo Niagara Medical Campus Master Plan Update has been awarded the 2012 Planning Excellence Award for Comprehensive Planning.  The 2012 NYUAPA Awards recognize outstanding work that is being done by planners and planning firms in Upstate New York.  Planning Excellence Award for Comprehensive Planning recognizes plans that advance the science and art of planning.

“The Four Neighborhoods, One Community plan used a visionary wp-contentroach that engaged stakeholder groups in a significant way and leveraged their collective knowledge to shape the final product,” said NYUAPA Awards Committee Chairman Mark Castiglione, AICP. “What’s more, not only does the plan include excellent analysis, writing, and graphics, but it builds on and seeks to implement existing community and neighborhood plans.  In doing so, the NYUAPA feel this plan is a model for others to emulate and is well deserving of this prestigious award.”

2012 Innovative Design Award by the Global Workspace Association 

This new, annual award was given out at GWA’s annual convention today in Baltimore, MD. The award is given to a member with a center who developed an innovative or unique design that positively affected client retention or center ‘sale-ability’ by addressing a particular challenge presented by the building or the environment. The Innovation Center was honored for tenant amenities such as exercise balls, Xbox Kinect, pool table, electric car chargers, and more.

 

 

 

The BNMC, Inc. is the umbrella organization created in 2001 by the institutions located within the Medical Campus. Our not-for-profit organization fosters conversation and collaboration among our member institutions, their 12,000 employees, and the community; coordinates activities related to sustainable planning, development and enhancement of our 120-acre space; and works to create a distinct, innovative environment that provides opportunities for entrepreneurship and active and healthy living.

RPCI Scientists Publish Findings About Novel Anticancer Agent

by BNMCin Member Institution(s), News, ResearchLeave a Comment on RPCI Scientists Publish Findings About Novel Anticancer Agent

FOR IMMEDIATE RELEASE
September 20, 2012
Contact: Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

RPCI Scientists Publish Findings About Novel Anticancer Agent
Camptothecin analog FL118 shown to inhibit production of key cancer survival genes

BUFFALO — Some 500,000 people die of cancer in the United States each year, often because their cancers have become resistant to wp-contentroved therapies. Scientists at Roswell Park Cancer Institute (RPCI) have made headway in the effort to overcome resistance to treatment, publishing findings about a novel cancer drug that has been shown to inhibit several genes associated with the ability of cancer cells to survive and reproduce.

A team led by Fengzhi Li, PhD, Associate Professor of Oncology in RPCI’s Department of Pharmacology and Therapeutics, assessed the antitumor effects of FL118, a camptothecin analog that is structurally similar to irinotecan and topotecan, in preclinical studies.

The ability of cancers to resist treatment with chemotherapy or radiation is rooted in the tendency of tumor cells to overproduce key genes that enable cancer cells to survive, such as survivin, Mcl-1, XIAP and cIAP2. Dr. Li and his colleagues found that FL118 inhibits expression of these genes in cancer cells and ultimately causes those tumor cells to die.

They also found that cancer cells die in the presence of FL118 even when the cells contained no p53, a key tumor-suppressing gene product. Because this protein is functionally eliminated in many cancers, it is important that cancer cells are sensitive to FL118 regardless of their p53 function. Preclinical studies showed a complete loss of detectable tumor mass in animal models following treatment with FL118, even for tumors that did not express “wild-type” p53 — a level of efficacy rarely seen with standard cancer therapies.

Importantly, FL118 was equally effective against tumor cells that are not normally considered to be resistant to therapy, and showed no wp-contentarent toxicity at these therapeutic levels.

“Our studies show that FL118 may become a superior option for effective control of both early and late-stage cancer, with or without metastasis,” said Dr. Li. “We still need to identify the exact biochemical targets as well as the pharmacokinetic and toxicological profile for FL118 before it goes into clinical studies, but we are encouraged by the implications of these compelling preclinical findings.”

The paper, “A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity,” published September 19 in PLOS ONE, is available at http://dx.plos.org/10.1371/journal.pone.0045571.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

-30-

Buffalo Niagara Medical Campus Receives Three Honors in One Day by Different International & State-Wide Organizations

by BNMCin Campus-wide, NewsLeave a Comment on Buffalo Niagara Medical Campus Receives Three Honors in One Day by Different International & State-Wide Organizations

Banner Letterhead
 

For Immediate Release  
Thursday, September 20, 2012                                                                  

For more information:
Contact Kari Bonaro
kbonaro@bnmc-old.local, 716-218-7157

 

Buffalo Niagara Medical Campus Receives Three Honors in One Day by Different International & State-Wide Organizations

Received Outstanding Research/Science Park, Planning Excellence, and Innovative Workspace Awards

(BUFFALO, NY) – The Buffalo Niagara Medical Campus received three honors on the same day this week: the BNMC was named 2012 Outstanding Research/Science Park by the Association of University Research Parks; its Four Neighborhoods, One Community: Buffalo Niagara Medical Campus Master Plan Update has been awarded the 2012 Planning Excellence Award for Comprehensive Planning by the New York Upstate Chapter of the American Planning Association (NYUAPA); and the Thomas R. Beecher Innovation Center, owned & operated by the BNMC, Inc.,  received the Innovative Design Award by international trade organization Global Workspace Association.

2012 Outstanding Research/ Science Park Award by Association of University Research Parks (AURP)

Patrick J. Whalen, Chief Operating Officer of the Buffalo Niagara Medical Campus, Inc., was on hand to accept the award at AURP’s annual conference in Madison, WI. The BNMC has submitted a proposal to host the group’s 2014 meeting here in Buffalo.

The Association of University Research Parks is a professional association of university related research and science parks. AURP’s mission is to foster innovation, commercialization and economic growth through university, industry and government partnerships. More online at www.aurp.net.

Previous parks honored as Outstanding Research/Science Park of the Year include the Research Park at the University of Illinois at Urbana-Champaign; Virginia Tech Corporate Research Center; Innovation Place (Saskatoon, Saskatchewan, Canada); Sandia Science & Technology Park (Albuquerque, NM); and Centennial Campus at North Carolina State University.

2012 Planning Excellence Award for Comprehensive Planning from the New York Upstate Chapter of the American Planning Association

In addition, the New York Upstate Chapter of the American Planning Association (NYUAPA) announced that the Four Neighborhoods, One Community: Buffalo Niagara Medical Campus Master Plan Update has been awarded the 2012 Planning Excellence Award for Comprehensive Planning.  The 2012 NYUAPA Awards recognize outstanding work that is being done by planners and planning firms in Upstate New York.  Planning Excellence Award for Comprehensive Planning recognizes plans that advance the science and art of planning.

“The Four Neighborhoods, One Community plan used a visionary wp-contentroach that engaged stakeholder groups in a significant way and leveraged their collective knowledge to shape the final product,” said NYUAPA Awards Committee Chairman Mark Castiglione, AICP. “What’s more, not only does the plan include excellent analysis, writing, and graphics, but it builds on and seeks to implement existing community and neighborhood plans.  In doing so, the NYUAPA feel this plan is a model for others to emulate and is well deserving of this prestigious award.”

2012 Innovative Design Award by the Global Workspace Association

This new, annual award was given out at GWA’s annual convention today in Baltimore, MD. The award is given to a member with a center who developed an innovative or unique design that positively affected client retention or center ‘sale-ability’ by addressing a particular challenge presented by the building or the environment. The Innovation Center was honored for tenant amenities such as exercise balls, Xbox Kinect, pool table, electric car chargers, and more.

About the BNMC

The Buffalo Niagara Medical Campus (BNMC) is dedicated to the cultivation of a world-class medical campus for clinical care, research, education, and entrepreneurship on 120 acres in downtown Buffalo. It is home to the region’s top clinical, research, and medical education institutions, including: the University at Buffalo, Roswell Park Cancer Institute, Olmsted Center for Sight, Kaleida Health, Hauptman-Woodward Medical Research Institute, Buffalo Medical Group, Buffalo Hearing & Speech Center, Unyts, and the Center for Hospice and Palliative Care. There are over 40 public and private companies on the BNMC. More than 12,000 people come to work at the Medical Campus every day, and BNMC institutions see over one million patients and visitors annually. The Campus has an annual economic impact of $1.5 billion on the region. The Medical Campus consists of more than 6 million square feet of research, clinical, and support space.  bnmc-old.local

About the BNMC, Inc.

The BNMC, Inc. is the umbrella organization created in 2001 by the institutions located within the Medical Campus. Our not-for-profit organization fosters conversation and collaboration among our member institutions, their 12,000 employees, and the community; coordinates activities related to sustainable planning, development and enhancement of our 120-acre space; and works to create a distinct, innovative environment that provides opportunities for entrepreneurship and active and healthy living. Learn more at bnmc-old.local.

 

###

RIA Takes the Challenge on Reducing College Student Substance Use

by BNMCin Campus-wide, Community, Member Institution(s), News, Research, WellnessLeave a Comment on RIA Takes the Challenge on Reducing College Student Substance Use

For release: September 20, 2012Contact: Sara R. Saldi, saldi@buffalo.edu
University at Buffalo
716-645-4593

RIA Takes the Challenge on Reducing College Student Substance Use

BUFFALO, N.Y. — No longer considered an innocent rite of passage, binge drinking among college students contributes to wp-contentroximately 1,800 deaths and nearly 600,000 injuries each year.

And that’s just alcohol.

The University at Buffalo’s Research Institute on Addictions (RIA), an internationally recognized leader on the subject of substance use and abuse since 1970, is tackling this problem head on.

This fall RIA will offer a three-pronged wp-contentroach to educating students, health care and mental health workers, and college administrators about the dangers, new trends and treatments for reducing substance use and excessive drinking in college kids.

RIA Director, Kenneth Leonard, PhD “Despite strong efforts, excessive alcohol and substance use among college students have not substantially diminished in the past decade. While many colleges have educational programs or referral services, many college administrators are not aware of or have not implemented services that have been shown to be the most effective.

“Therefore, there is a pressing need for a more active and ongoing dialogue among researchers, practitioners and administrators regarding the current state of knowledge about college student drinking and substance use—a dialog that will also benefit parents and their children in college.”

A photo of Leonard is available at: http://www.buffalo.edu/news/13681.

First, the RIA is releasing the fifth in its series of expert summaries, “RIA Reaching Others: College Student Drinking,” a fact sheet describing the dangers of college student drinking, especially binge drinking—the scope of the problem, specific points for parents and the value of prevention.

The fact sheet is available at: http://www.ria.buffalo.edu/ExpertSummaries/ES5.html.

Second, as part of RIA’s Fall 2012 Seminar Series, Mark Wood,  PhD, a professor in the Department of Psychology at the University of Rhode Island (URI) and an expert on substance use among college students, will speak on “Individual and Environmental Preventive Intervention to Reduce Collegiate Alcohol Abuse: A Full-Cycle Approach.”

His presentation will be at 10 a.m. Oct. 26 in Room 132 of the RIA building, 1021 Main St. on the Buffalo Niagara Medical Campus. It will be free and open to the public.

For more information on the Wood presentation, visit: http://www.ria.buffalo.edu/events/index.html

Third, RIA is hosting a two-day conference, titled “The Challenge of Reducing College Student Substance Use: A Conversation in the Disciplines,” to take place Nov. 8 and 9 in the Ramada Hotel and Conference Center, 2402 North Forest Road near the Audubon Parkway in Getzville, adjacent to the UB North Campus.

The two-day event will feature alcohol and substance use experts from UB and from across the state.  It is sponsored by the Conversations in the Disciplines Program of the State University of New York.

The conference will bring together front-line staff from throughout the SUNY system who grwp-contentle with the real problems of college students’ alcohol and substance use and abuse, and the researchers who seek to develop and evaluate substance-use prevention and intervention strategies. It also will provide an opportunity for participants to present information about their programs and to discuss issues regarding the startup and operation of effective programs.

Even more importantly, however, the conference will explore the potential for developing a multi-campus network of researchers and practitioners across New York State to address excessive college student substance use.

“This will facilitate the development and evaluation of innovative and comprehensive wp-contentroaches to reducing substance use, and provide a communications network that will enhance the efforts of practitioners to offer the most effective strategies for their campuses,” Leonard said.

Information about the conference and how to register are available at http://www.ria.buffalo.edu/CID2012/index.htm

Discovery of Essential Genes for Drug-Resistant Bacteria Reveals New, High-Value Drug Targets

by BNMCin Member Institution(s), News, ResearchLeave a Comment on Discovery of Essential Genes for Drug-Resistant Bacteria Reveals New, High-Value Drug Targets

Release Date: September 14, 2012Contact: Ellen Goldbaum, goldbaum@buffalo.edu
University at Buffalo
716-645-4605

Discovery of Essential Genes for Drug-Resistant Bacteria Reveals New, High-Value Drug Targets

By studying A. baumannii under “clinically relevant” conditions, the researchers have a more precise understanding of how the bacteria infects humans — and how best to fight it

BUFFALO, N.Y. — Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria.  The study not only reveals multiple, new drug targets for this human infection, it also suggests that the typical methods of studying bacteria in rich laboratory media may not be the best way to identify much-needed antimicrobial drug targets.

The paper (http://mbio.asm.org/content/3/4/e00113-12) focuses on a Gram-negative bacteria called A. baumanni. It is published in the current issue of mBio, as an ‘editor’s choice’ paper. The findings may be relevant to other Gram-negative bacteria as well. (A graphic related to the research is at http://www.buffalo.edu/news/13673.)

A. baumannii is responsible for a growing number of hospital-acquired infections around the world. It can be fatal to patients with serious illnesses, the elderly and those who have had surgeries. Infections also have been seen in soldiers returning from Iraq and Afghanistan with battlefield injuries.

“Generally, healthy people don’t get infected,” explains lead author Timothy C. Umland, PhD, research scientist at Hauptman-Woodward Medical Research Institute (HWI) and professor of structural biology in the University at Buffalo School of Medicine and Biomedical Sciences.  “But what’s challenging about A. baumannii is that it can survive in the hospital environment and is very hard to eradicate with common disinfectants, leading to healthcare-associated infections.”

Typically, the way that essential genes for microbial pathogens are found is by growing the bacteria under optimal conditions, says co-author Thomas A. Russo, MD, professor in the UB departments of medicine and microbiology and immunology. Genes found to be essential for growth are then entered into the Database of Essential Genes (DEG), which contains genes considered essential for the sustenance of each organism.

The researchers at HWI and UB decided to try to better understand what A. baumannii needs in order to grow when infecting patients.

“Laboratory conditions create a different type of environment from what hwp-contentens in patients,” Umland says, “where certain nutrients the bacteria need will be present in very low amounts and where the bacteria encounter immune and inflammatory responses. We were purposely trying to test for genes that are important for growth in these more realistic environments.”

The team performed a genetic screen designed to identify bacterial genes absolutely required for the growth and survival of A. baumannii in human ascites, a peritoneal fluid that accumulates under a variety of pathologic conditions.

“We found that nearly all of these 18 genes had not been identified as essential in the DEG because they weren’t necessary for growth in an ideal laboratory environment,” explains Russo. “This is a large set of genes that has been flying under the radar.”

He adds: “The biggest concern is that quite a few strains of A. baumannii are resistant to nearly all anti-microbial drugs and some strains are resistant to all of them. To make things worse, there are no new agents being tested for human use in the drug pipeline that are active against A. baumannii. This is a huge problem.”

Not only do the new genes suggest brand new, high-value drug targets for A. baumannii infections, but the genes that have been identified may be relevant to other Gram-negative infections.

“So far, our computational models show that these genes seem to be conserved across Gram-negative infections, meaning that they may lead to new drugs that would be effective for other drug-resistant infections as well,” says Umland.

The researchers who collaborated on the study are now pursuing antibacterial drug discovery efforts focused on the newly identified bacterial targets.

The research was funded by grants from the Telemedicine and Advance Technical Research Center of the U.S. Army Medical Research and Materiel Command, an interdisciplinary grant from UB and a VA Merit Review grant from the U.S. Department of Veterans Affairs.

Other co-authors are: L. Wayne Schultz, PhD, of HWI and UB, and Ulrike MacDonald, Janet M. Beanan and Ruth Olson of the UB Department of Medicine, the Department of Microbiology and Immunology and UB’s Witebsky Center for Microbial Pathogenesis.

Researchers Create Approach to Analyze Genetic Disease Data More Efficiently

by BNMCin Campus-wide, Homepage, Member Institution(s), News, ResearchLeave a Comment on Researchers Create Approach to Analyze Genetic Disease Data More Efficiently

Collaborating with the Center for Human Genome Variation at Duke University, Roswell Park Cancer Institute (RPCI) researchers have developed a method to dexterously determine genetic factors that cause disease.
In a recent research study published in The American Journal of Human Genetics, RPCI’s Dr. Qiangian Zhu and fellow researchers have established a computational method called the “preferential linkage disequilibrium” wp-contentroach to isolate causal variants, the genetic irregularities that suggest the presence of a particular disease.

Dr. Zhu is a biostatician who is also the Assistant Member of the Department of Biostatistics and Bioinformatics and the Director of Statistical Genetics and Genomics Resource at RPCI. Her research interests lie in developing statistically sound and computationally efficient methods to find the causal genetic variants of human diseases and traits utilizing high-throughput genetics and genomics data.

Continuing her postdoctoral research after joining RPCI, Dr. Zhu, along with her research collaborators, used variants recorded from genome-wide association studies (GWASs) that analyze people’s DNA to capture genetic variations associated with a disease. The group of researchers cross-referenced variants with a comprehensive variant catalog generated through robust “next generation” sequencing in order to identify the causal variants.

The study examined the DNA from 479 individuals of European descent. “To test our method, we ran it on five diseases for which the causal variants are known, and in every case we did identify the real causal variant,” said Zhu. The group hopes to have the method wp-contentlied to GWASs related to diseases that do not have specific causal variants, resulting in advances towards the development of targeted wp-contentroaches to treating diseases.

Fellow author of the study, David B. Goldstein, Richard and Pat Johnson Distinguished University Professor and Director of the Center for Human Genome Variation at DUMC stated that “This wp-contentroach helps to intergrade the large body of data available in GWASs with the rapidly accumulating sequence data.”

Learn more about the study: Prioritizing Genetic Variants for Causality on the Basis of Preferential Linkage Disequilibrium

National Study Recommends Smoke-Free Apartment Policies

by BNMCin Environment, Health care, Healthy Communities, Member Institution(s), News, WellnessLeave a Comment on National Study Recommends Smoke-Free Apartment Policies

FOR IMMEDIATE RELEASESeptember 10, 2012
Contact: Annie Deck-Miller, Senior Media Relations Manager
716-845-8593; annie.deck-miller@roswellpark.org

National Study Recommends Smoke-Free Apartment Policies
Majority of those surveyed support policies prohibiting smoking anywhere in multi-tenant residential buildings

BUFFALO — A majority of Americans who live in multi-unit housing have adopted smoke-free rules in their private homes but millions remain involuntarily exposed to secondhand smoke in this environment, according to a study published in the most recent issue of the American Journal of Public Health. Researchers led by senior investigator Andrew Hyland, PhD, Chair of the Department of Health Behavior at Roswell Park Cancer Institute (RPCI), recommend smoke-free building policies to protect all multiunit residents from secondhand smoke exposure in their homes.

“A vast majority of multi-unit housing residents continue to be exposed to toxic compounds found in secondhand smoke in spite of the adoption of voluntary smoke-free rules for their private homes,” said Dr. Hyland. “This study demonstrates widespread support of the adoption of smoke-free building policies.”

The national study evaluated attitudes, experiences and acceptance of smoke-free policies among residents of multi-unit housing in the United States. Approximately 80 million Americans live in multi-unit housing. Using the results of this study, the researchers estimate that 30 million multi-unit housing residents with smoke-free rules in their homes may still be exposed to tobacco smoke that enters their residence from other areas of the building.

Hyland and colleagues conducted a nationally representative survey of multi-unit housing residents who live in apartments, duplexes, double/multifamily homes, condominiums or town houses was 2010. The study sample included both landline and cell-phone-only users. Overall, 29% reported living in smoke-free buildings. Among all respondents, 56% support the implementation of policies prohibiting smoking in all areas of their building, including living units and common areas.

The study also found that 79% of multiunit housing residents have implemented voluntary smoke-free home rules. Those who have reported having these rules were more likely to be non-smokers, have higher education and live with children. Forty-four percent of those with smoke-free rules at home reported being exposed to secondhand smoke in the past year that originated from smoking in other parts of their buildings.

“Residents of multi-unit housing are particularly susceptible to secondhand smoke exposure from nearby units and shared areas such as hallways,” said lead author Andrea Licht, MS, a doctoral student with the Department of Social and Preventive Medicine at the University at Buffalo. “These residents are trying to protect their families from the dangers of secondhand smoke by not allowing smoking in their homes and would welcome policies that support that goal.”

The publication, “Attitudes, Experiences, and Acceptance of Smoke-Free Polices Among U.S. Multi-unit Housing Residents” can be found at http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2012.300717.

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. RPCI, founded in 1898, was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit RPCI’s website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org.

-30-

WTCBN Receives Funds to Help Increase Medical Device Trade Between WNY Manufacturers and China

by BNMCin Entrepreneurs, Investment Opportunities, NewsLeave a Comment on WTCBN Receives Funds to Help Increase Medical Device Trade Between WNY Manufacturers and China

The World Trade Center of Buffalo Niagara (WTCBN), a local not-for-profit international business development organization helping to facilitate regional growth through global trade, has received nearly $682,000 to help increase medical device trade between Western New York (WNY) manufacturers and China. In that pot of money is $218,000 from the U.S. Department of Commerce.
Through a program that will be  administered over a three-year time period, WTCBN and partners that work with medical device companies will enhance trade relations knowledge to place devices in one of the largest populace nations in the world. Partners include the University at Buffalo’s New York State Center of Excellence in Bioinformatics and Life Sciences, the Buffalo Niagara Medical Campus, The Buffalo Niagara Partnership, MedTech, the Jacobs Institute and the Department of Commerce, in addition to others who assist and house medical device companies.

“This three-year project will serve as a template for a greater regional export strategy,” said Chris Johnston, president of WTCBN. Johnston also stated that it will be “a great opportunity for collaboration among various groups, including the federal, state and regional government, with local organizations such as the Buffalo Niagara Medical Campus, UB and World Trade Center Buffalo Niagara, which will maximize the benefits for Western New York companies.”

The Accelerating Upstate New York’s Competitiveness and Exports in the Global Economy program will offer training and expertise to least 40 local manufacturers, teaching them how to navigate Chinese import laws, how to effectively market their products in China and the logistics of shipping goods there. They will also provide access to export loans and credit insurance. An estimated $25 million could come from Chinese contracts over a four-year period, leading to the creation of  hundreds of  jobs in this area.

At a roundtable discussion moderated by Congresswoman Kathy Hochul, New York’s 26th Congressional District Representative, companies had the opportunity to ask questions and receive feedback on how to identify and capitalize on new medical device markets, and to learn more about the program. Congresswoman Hochul said the program is “a critical step toward opening new markets, fostering innovation, and expanding manufacturing right here at home. Meaningful investment in Western New York’s medical device industry and work force will help add good-paying, sustainable jobs to our local economy.” The discussion served as an indicator of the collaboration and knowledge-sharing between experts and companies that is soon to come.

Congresswoman Hochul also said “It is vital that we continue to work to ensure our local businesses have the resources necessary to expand and reach new global markets.” With over $1.9 trillion in exportation of goods and services in 2011, China is currently the largest exporting country in the world. Efforts to increase the importation of medical devices made from the U.S., more so in the WNY region to China, will undeniably generate revenue increases for many local companies.

The U.S. Commerce Secretary, Rebecca Blank, stated that “The awards given by the Commerce Department’s Market Development Cooperator Program will help us continue to make progress toward achieving the President Obama’s goal of doubling exports by the end of 2014. Higher exports lead to more jobs: in 2011, jobs supported by exports increased by 1.2 million over 2009.”

The Buffalo Niagara Medical Campus, Inc.’s COO, Patrick J. Whalen stated that “the Department of Commerce grant will showcase the assets in Western New York to medical device companies around the world, and we look forward to working together to help existing companies succeed and grow.”

While WNY is home to nearly 250 medical equipment manufacturers and medical research centers, WTCBN reports that an overwhelming majority of the companies export their goods to the one country it is closest to which is Canada. Past innovations from the region include the implantable pacemaker, the Prostate-Specific Antigen (PSA) test, photodynamic therapy (used to treat malignant cancers), and multiple sclerosis therapy.

The inaugural session of the 2012-13 Life Sciences Commercialization Lecture Series will present an opportunity for local companies to learn more about the program. The session will take place on Thursday, September 27 from 4-5 p.m. at the New York State Center of Excellence in Bioinformatics and Life Sciences located at 701 Ellicott Street. For more information and to register for the event, click here.

Class of 2016 Participates in UB's Pharmacy Practice White Coat Ceremony

by BNMCin Member Institution(s), NewsLeave a Comment on Class of 2016 Participates in UB's Pharmacy Practice White Coat Ceremony

News Release

Class of 2016 Participates in UB’s Pharmacy Practice White Coat Ceremony

[ photograph ]
The PharmD class of 2016 at the White Coat Ceremony

Contact

Sara Saldi

saldi@buffalo.edu

716-645-4593

Release Date: September 4, 2012

BUFFALO, N.Y. — One hundred and twenty-six students took their first, public step toward becoming pharmacists when they participated in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences Annual White Coat Ceremony 2012 in the Lippes Concert Hall on Aug. 23.

The White Coat Ceremony symbolizes passage into the initial stages of the profession of pharmacy practice and represents a contract for excellence in providing compassionate patient care.

This event also highlights the importance of scientific scholarship and emphasizes the highest principles of moral, ethical and legal conduct. UB PharmD students taking part in this tradition are welcomed to begin study among the ranks of pharmacy professionals.

During the “Calling of the Class,” each of the students in the Class of 2016 were called to the stage to be presented with their coat while their hometown was identified by Karl D. Fiebelkorn, RPh, MBA and UB associate dean for student affairs and professional relations.

Wayne K. Anderson, PhD, dean and professor of the UB’s School of Pharmacy and Pharmaceutical Sciences, gave the welcome.

Keith Wagner, PharmD, ’00, MBA, ’03 and MBA director of trade and specialty accounts for Eli Lilly and Company, gave the keynote address.

Safe Routes to School Program Launches at PS 74

by BNMCin Biking, Community, Healthy Communities, Homepage, News, Outreach, Transportation, WellnessLeave a Comment on Safe Routes to School Program Launches at PS 74

GO Bike Buffalo has launched the Buffalo Safe Routes to School Program (SRTS) at Hamlin Park School 74 . A part of a national program promoting the benefits of walking and biking to school  for students, SRTS seeks to help students become more physically active.  SRTS also aims to reduce vehicle congestion around schools, resulting in safer access and lower exhaust emissions.
Through a technology class at Hamilton Park, the Recycle-A-Bicycle (RAB) program will be incorporated into the curriculum. At Hamlin Park, students will learn how to build bicycles using salvaged parts and they will be taught how to make environmentally sound transportation choices which will undoubtedly have an impact on the health of the communities they live in. As they grow in their understanding of the importance of being physically active, the SRTS program will also teach them how to ride bicycles safely.

With the support of City Hall representative, Council Member Demone Smith, the program’s success will most likely be included into additional Buffalo Public Schools as a useful educational program. Smith stated that “Instituting healthy lifestyles and behaviors early in life are essential to developing healthy young people and communities.  We will continue to work with GO Bike Buffalo to make improvements in the District as well as among our youngest residents.”

At International Cardiology Meeting, UB Chair of Medicine is Honored for Her Distinguished Clinical Research

by BNMCin Member Institution(s), News, ResearchLeave a Comment on At International Cardiology Meeting, UB Chair of Medicine is Honored for Her Distinguished Clinical Research

News Release

At International Cardiology Meeting, UB Chair of Medicine is Honored for Her Distinguished Clinical Research

[ photograph ]
UB’s Curtis is one of the world’s leading clinical cardiac electrophysiologists and an expert in cardiac arrhythmias.

Contact

Ellen Goldbaum

goldbaum@buffalo.edu

716-645-4605
twitter @egoldbaum

Release Date: August 22, 2012

BUFFALO, N.Y. — Anne B. Curtis, MD, Charles and Mary Bauer Professor and Chair of the Department of Medicine in the University at Buffalo School of Medicine and Biomedical Sciences, has been awarded the Walter Bleifeld Memorial Award for Distinguished Work in Clinical Research. Bleifeld, considered one of the pioneers of modern cardiology, was a professor of medicine and cardiology at the University of Hamburg.

Curtis was presented with the award in July at the 17th World Congress on Heart Disease of the International Academy of Cardiology in Toronto.

The award recognizes Curtis’s outstanding contributions to clinical research. She is one of the world’s leading clinical cardiac electrophysiologists and an expert in cardiac arrhythmias. Her clinical research has significantly advanced knowledge of human cardiac electrophysiology and heart-rhythm abnormalities.

Curtis’s research interests include clinical trials in implantable device therapy for prevention of sudden cardiac death and management of heart failure, as well as clinical trials in atrial fibrillation. She has been principal investigator, co-investigator, sponsor or steering committee member on 85 research studies and clinical trials and has written more than 250 peer-reviewed manuscripts, book chapters, reviews and editorials. She also is author of a book on cardiac pacing.

Curtis received a 2010 Distinguished Fellowship Award from the International Academy of Cardiology.

In 2011, she was a key contributor to guidelines on atrial fibrillation that are issued periodically by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Earlier this year, she received the 2012 Distinguished Service Award from the Heart Rhythm Society.

She lives in Buffalo.

Medications Can Help with Smoking Cessation

by BNMCin Environment, Healthy Communities, Homepage, Member Institution(s), WellnessLeave a Comment on Medications Can Help with Smoking Cessation

A new study conducted by researchers at Roswell Park Cancer Institute (RPCI) shows that FDA-wp-contentroved stop-smoking medications can help smokers who desire to quit. By using the stop-smoking medications, the chances of quitting successfully increase.
The study was published online in the British journal Addiction. Clinical trials have shown that medications such as nicotine replacement therapy (NRT), bupropion and varenicline have been effective even though population-based studies have produced mixed results on effectiveness when medications are used outside the confines of a research study.

The International Tobacco Control (ITC) research collaboration has administered one of the largest real-world evaluations of medication effectiveness conducted to-date. They are also the first to comprehensively control biases in participants’ recall of quit attempts. The study tracked the smoking behaviors of more than 2,500 adult smokers in the United Kingdom, Canada, Australia and the United States who reported making a quit attempt between 2006 and 2009. The participants were asked how recently they had attempted to quit and whether they used any type of stop-smoking medication. Six-month continuous abstinence among those who recalled making a very recent quit attempt was assessed at the next follow-up interview. The results showed that those who used varenicline, bupropion or the nicotine patch had much higher quit success at six months compared to those who tried to quit without using medication.

“By restricting our analyses to those who made very recent quit attempts, we reduced the extent to which differences in quit-attempt recall could bias the estimates of medication effectiveness. Consistent with the strong evidence from clinical trials, our findings show that medications are indeed effective in increasing smokers’ chances of quitting when used in the real world,” said Karin Kasza, MA, statistician in the Division of Cancer Prevention & Population Sciences at RPCI and lead author of the study.

Ron Borland, PhD, Nigel Gray Distinguished Fellow in Cancer Prevention at the Cancer Council Victoria in Melbourne, Australia and a co-author of the study, added, “The major advance of this study is that we have been able to show that greater forgetting of unassisted failed attempts is the most likely reason other studies have not found a benefit for medication in population-based settings. This finding should reassure clinicians and public health workers to continue to encourage the widespread use of medications.”

“Despite the benefit of using medications, many smokers still try to quit without help. And even when medications are used, quitting smoking is hard, and relapses are common. Continued efforts are needed to develop and deliver more effective treatments to help smokers who want to quit,” said Andrew Hyland, PhD, Chair of the Department of Health Behavior at RPCI.

The study, “Effectiveness of Stop-Smoking Medications: Findings from the International Tobacco Control (ITC) Four Country Survey,” can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.2012.04009.x/abstract

RPCI Welcomes New Vice Chair to Surgical Oncology Team

by BNMCin Homepage, Member Institution(s), NewsLeave a Comment on RPCI Welcomes New Vice Chair to Surgical Oncology Team

Steven Hochwald, MD, FACS, has joined Roswell Park Cancer Institute (RPCI) as Vice Chair, Chief of Gastrointestinal (GI) Surgery and Professor of Oncology in the Department of Surgical Oncology.
He is the former University of Florida Edward M. Copeland Professor of Surgical Oncology. He was also the Chief of the Division of Surgical Oncology and Physician Leader of the GI Oncology Center at the University of Florida’s Shands Cancer Center. His research focuses on technical advances in minimally invasive esophageal and GI surgeries and developing new targets and agents for treatment of pancreatic and other GI cancers.

A graduate of John Hopkins University, Dr. Hochwald went on to receive an MD from New York University (NYU). He did his residency at the NYU Medical Center Department of Surgery, serving as Executive Chief Resident from 1996-97, and completed clinical and research fellowships in surgical oncology at Memorial Sloan-Kettering Cancer Center.

“There’s a well-developed infrastructure in Roswell Park’s surgical program and a collaborative atmosphere throughout the institution,” said Dr. Hochwald. “The Institute is poised to make significant advances that will benefit cancer patients, and I’m very pleased to be working alongside this outstanding team.”

He was featured on the Best Doctors, Inc.’s Best Doctors list. In 2007, Dr. Hochwald received the Cancer Liaison Physician Outstanding Performance Award from the Commission on Cancer. He is a member of many professional societies. He serves on numerous editorial boards including: Open Surgical Oncology Journal, World Journal of Gastrointestinal Oncology, International Journal of Surgical Oncology, World Journal of Gastroenterology, Gastroenterology and Hepatology, World Journal of Surgical Procedures and Cancer Reports. He has also served on several National Institutes of Health study sections and scientific advisory boards for the American Cancer Society.

“Dr. Hochwald has been a terrific addition to our surgical team,” said William Cance, MD, FACS, Surgeon-in-Chief and Chair of the Department of Surgical Oncology. “He brings so much as a surgeon, in his interactions with patients, as a mentor and instructor, and his research complements our program beautifully.”

UB CAT Awards More Than $415,000 to 16 WNY Companies Developing Life Sciences Technologies

by BNMCin Life Sciences Companies, Member Institution(s), NewsLeave a Comment on UB CAT Awards More Than $415,000 to 16 WNY Companies Developing Life Sciences Technologies

News Release

UB CAT Awards More Than $415,000 to 16 WNY Companies Developing Life Sciences Technologies

Contact

Marcene Robinson

marcener@buffalo.edu

716-645-4650

Release Date: July 18, 2012

BUFFALO, N.Y. — The University at Buffalo Center for Advanced Biomedical and Bioengineering Technology (UB CAT) has awarded more than $415,000 to companies in Western New York to aid them in the development of new life sciences technologies.

The funding will support a range of projects in the 2012-13 fiscal year, from development of eye-controlled keyboards to development of a new cancer immunotherapy. Companies must work with a UB professor as principal investigator, and also get access to UB facilities and equipment.

Firms receiving an award, which typically ranges between $10,000 and $50,000, must match the funding with their own money.

The UB CAT is one of 15 centers across New York State that Empire State Development’s Division of Science, Technology and Innovation (NYSTAR) funds to support university-industry collaboration in research, education and technology transfer. The focus is on linking academic research with commercial interests to help New York State-based businesses gain a technological edge on their competition.

UB received its most recent re-designation by NYSTAR as a Center for Advanced Technology in 2007. The designation lasts 10 years, during which the UB CAT receives nearly $1 million annually from NYSTAR.

Since 2005, the UB CAT has supported over 75 projects leading to more than $140 million in non-job economic impact. The center has also helped Western New York’s life sciences sector create over 280 new jobs.

“The UB CAT provides companies with funding and resources during a critical stage in the development of new technologies,” said Marnie LaVigne, UB associate vice president for economic development. “The projects we have supported over the years have helped create jobs in New York State, facilitated long-term partnerships between UB and industry, and led to the commercialization of new and improved life sciences products and services.”

This year, 16 businesses were chosen from a group of 22 wp-contentlicants, all vying for aid in creating new technologies that benefit the fields of health and medicine.

One such company, IMMCO Diagnostics Inc., will use its $40,000 award to develop a more sensitive and specific test for Sjogren’s syndrome, an autoimmune disease in which white blood cells attack the glands that produce tears and saliva.

The syndrome is the second most common autoimmune disease, affecting some 4 million Americans. Nine out of 10 patients are women, including tennis champion Venus Williams.

Williams was first diagnosed with this disease in 2011, but suffered with Sjogren’s for a while before doctors could determine the cause.

Current tests for Sjogren’s syndrome are not sensitive enough, missing almost two-thirds of cases. However, research by Julian Ambrus Jr., MD, rheumatologist, immunologist and an associate professor in UB’s Department of Medicine, led to the discovery of a diminished protein in those with the syndrome.

IMMCO, founded in Buffalo in 1971 by several UB professors, is one of the world’s first autoimmune disease diagnostic companies. Their lab will manufacture the new testing kits, which will detect the disease in 70 to 80 percent of patients.

“Most autoimmune diseases are difficult to diagnose, simply because we really do not know the exact causes for most of them,” said Lakshmanan Suresh, assistant vice president of lab services at IMMCO. “This collaboration between IMMCO and UB will help diagnose the disease earlier so treatment can be delivered sooner.”

He adds, “The grant also helps us get this test from the bench stage to the market quicker.”

Information regarding the UB CAT and the center’s award wp-contentlication process is available online at http://www.bioinformatics.buffalo.edu/cat.php.

UB Department of Medicine Names Head of Gastroenterology Division

by BNMCin Member Institution(s), News, ResearchLeave a Comment on UB Department of Medicine Names Head of Gastroenterology Division

News Release

UB Department of Medicine Names Head of Gastroenterology Division

[ photograph ]Andrew H. Talal, MD, MPH, has been named chief of the Division of Gastroenterology, Hepatology, and Nutrition.Download JPEG

Contact

Sara Saldi

saldi@buffalo.edu

716-645-4593

Release Date: July 17, 2012

BUFFALO, N.Y. — Andrew H. Talal, MD, MPH, associate professor at the Weill Cornell Medical College has been named chief of the Division of Gastroenterology, Hepatology, and Nutrition in the University at Buffalo’s Department of Medicine; he also has been wp-contentointed UB professor of medicine.

The announcement was made by Anne B. Curtis, MD, Charles and Mary Bauer Professor and Chair of the Department of Medicine in UB’s School of Medicine and Biomedical Sciences.

Talal will join UB in September, when Thomas Mahl, MD, clinical professor, who recently served as interim chief, steps down; previously Michael Sitrin, MD, professor, had been leading the division.

Talal has an international reputation for his clinical and translational work in hepatology, the branch of medicine that deals with the liver, gallbladder, biliary tree and pancreas, and management of these disorders. He has been recognized as an authority on viral hepatitis in HIV-infected individuals. A board-certified gastroenterologist and hepatologist, he is a physician-scientist in the Center for the Study of Hepatitis C, a consortium between Rockefeller University, Weill Cornell Medical College and New York Presbyterian Hospital.

His research interests include: the development of biomarkers of the progression and treatment outcomes in hepatitis C virus (HCV) infection; the evaluation of hepatitis C virus-specific immune responses in injection drug users; treatment outcomes in special populations infected with hepatitis C virus (HIV/HCV co-infection, methadone maintenance, patients with bleeding disorders and thalassemia); and novel treatments for hepatitis C.

Talal currently is conducting research funded by such federal agencies as the National Institutes of Health and the Centers for Disease Control on HCV evaluation and treatment among patients in drug treatment programs and risk factors for AIDS among IV drug users.

Talal was the recipient of a Clinton Global Initiatives award from the W.J. Clinton Foundation in 2006, which fostered the development of treatment algorithms for hepatitis viruses B and C.

Talal earned his MD from the University of Texas Health Science Center in San Antonio and received his MPH from the University of North Carolina. He completed his medical residency at the University of Iowa and research and clinical fellowships in gastroenterology at the University of North Carolina.

Before joining the Weill Cornell Medical College, he was a research associate and clinical scholar at the Rockefeller University in New York.

Real-life Spider Men Using Protein Found in Venom to Develop Muscular Dystrophy Treatment

by BNMCin Member Institution(s), News, Research, WellnessLeave a Comment on Real-life Spider Men Using Protein Found in Venom to Develop Muscular Dystrophy Treatment

News Release

Real-life Spider Men Using Protein Found in Venom to Develop Muscular Dystrophy Treatment

A grandfather is working with UB scientists in an attempt to save grandson’s life

JB, Jeff Harvey’s grandson. When Harvey discovered JB had Duchenne muscular dystrophy, the grandfather started a company with UB researchers to develop a treatment.
UB researchers Frederick Sachs, Tom Suchyna and Philip Gottlieb are working to develop a treatment for muscular dystrophy using a peptide found in tarantula venom.
UB researchers are developing a treatment for muscular dystrophy using a peptide found in the venom of a Chilean rose tarantula.

Contact

Charlotte Hsu

chsu22@buffalo.edu

716-645-4655

Release Date: July 16, 2012

BUFFALO, N.Y. — While Spider-Man is capturing the imagination of theatergoers, real-life spider men in Upstate New York are working intently to save a young boy’s life.

It all began in 2009, when Jeff Harvey, a stockbroker from the Buffalo suburbs, discovered that his grandson, JB, had Duchenne muscular dystrophy. The disease is fatal. It strikes only boys, causing their muscles to waste away.

Hoping to help his grandson, Harvey searched Google for promising muscular dystrophy treatments and, in a moment of serendipity, stumbled upon University at Buffalo scientist Frederick Sachs, PhD.

Sachs was a professor of physiology and biophysics who had been studying the medical benefits of venom. In the venom of the Chilean rose tarantula, he and his colleagues discovered a protein that held promise for keeping muscular dystrophy at bay. Specifically, the protein helped stop muscle cells from deteriorating.

Within months of getting in touch, Harvey and Sachs co-founded Tonus Therapeutics, a pharmaceutical company devoted to developing the protein as a drug. Though the treatment has yet to be tested in humans, it has helped dystrophic mice gain strength in preliminary experiments.

The therapy is not a cure. But if it works in humans, it could extend the lives of children like JB for years — maybe even decades.

Success can’t come quickly enough.

JB, now four, can’t walk down the stairs alone. When he runs, he waddles. He receives physical therapy and takes steroids as a treatment. While playing tee ball one recent day, he confided to his grandfather, “When I grow up, I want to be a baseball player.”

It was a heartbreaking moment.

“Oh, I would be thrilled if you could be a baseball player,” Harvey remembers replying. He’s doing everything he can to make sure that JB — and other boys like him — can live out their dreams.

For the complete story and multimedia, visit http://www.buffalo.edu/home/feature_story/good-venom.html.

UB Medical School Names Dubocovich Senior Associate Dean for Inclusion and Cultural Enhancement

by BNMCin Member Institution(s), NewsLeave a Comment on UB Medical School Names Dubocovich Senior Associate Dean for Inclusion and Cultural Enhancement

News Release

UB Medical School Names Dubocovich Senior Associate Dean for Inclusion and Cultural Enhancement

New post reflects UB medical school’s emphasis on attracting — and serving — culturally diverse populations

[ photograph ]
UB’s Dubocovich is the new senior associate dean for inclusion and cultural enhancement in the UB School of Medicine and Biomedical Sciences.

Contact

Ellen Goldbaum

goldbaum@buffalo.edu

716-645-4605
twitter @egoldbaum

Release Date: July 13, 2012

BUFFALO, N.Y. — Margarita L. Dubocovich, PhD, chair of the University at Buffalo’s Department of Pharmacology and Toxicology, has been named the inaugural senior associate dean for inclusion and cultural enhancement in the UB School of Medicine and Biomedical Sciences. She will continue to serve as chair of the UB Department of Pharmacology and Toxicology.

In making the announcement, Michael E. Cain, MD, vice president for health sciences at UB and dean of the medical school, said: “In addition to being an outstanding scientist in molecular pharmacology and drug discovery, Dr. Dubocovich has the expertise, administrative leadership and visionary skills needed to develop and implement through the new Office of Inclusion and Cultural Enhancement innovative programs that insure the school and the university are enriched through cultural enhancement.”

Cain explains that the new post was established in line with the school’s diversity policy, which seeks inclusion and cultural enhancement as a means toward achieving excellence for students and faculty, enriching the learning environment, strengthening the school’s ties to nearby communities and contributing in measurable ways to improving the health of the community.

“Diversity within medical school classes enhances the educational environment,” he said, “by helping students to break down stereotypes and racial biases and challenge assumptions; broadening students’ understanding of how language and culture affect medical care; teaching how embracing differences in race, ethnicity and other cultural experiences can enhance interactions between doctors, patients and their families; increasing students’ awareness of health and health care disparities in nearby populations; and increasing students’ interest in service to underserved communities and overall civic commitment.”

In 2008, Dubocovich was recruited to UB from Northwestern University, where she had founded and directed a highly successful professional development program for a diverse group of doctoral students in the biosciences.

In her first full year in Buffalo, she established a similar series of programs at UB, called Collaborative Learning and Integrated Mentoring in the Biosciences (CLIMB), which provides mentoring experiences for biosciences students at the undergraduate, graduate and postdoctoral levels. The goal is to provide students from diverse populations the support they need to adapt and thrive in the biosciences, in college, graduate school and beyond.

This year, the program for graduate students, led by Dubocovich, was awarded a $1.9 million National Institutes of Health Initiative for Maximizing Student Development grant.

Cain said that the CLIMB programs complement the medical school’s other innovative Post-Baccalaureate Program and Science and Technology Entry Program (STEP) initiatives.